Avidity Biosciences Inc. (RNA) is scheduled to present new long-term efficacy and safety data from its MARINA-OLE trial at the Muscular Dystrophy Association Clinical & Scientific Conference on March 4, 2024.
MARINA-OLE trial is a Phase 2 extension of the MARINA study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of lead drug candidate AOC 1001 administered intravenously to adult Myotonic Dystrophy Type 1 (DM1) patients.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com